CHAPTER 68 — REFERENCES


Chapter 68 

References


144. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of
141. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for pre-
130. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: a mul-
139. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mor-
134. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee
133. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
136. Smith MR. Bisphosphonates to prevent skeletal complications in men with
154. Food and Drug Administration. 
158. Smith MR. Bisphosphonates to prevent skeletal complications in men with
156. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
152. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate can-
141. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for pre-
139. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mor-
134. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee
133. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
136. Smith MR. Bisphosphonates to prevent skeletal complications in men with
152. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate can-
155. Food and Drug Administration. 
158. Smith MR. Bisphosphonates to prevent skeletal complications in men with
156. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
152. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate can-
155. Food and Drug Administration. 
158. Smith MR. Bisphosphonates to prevent skeletal complications in men with
156. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
152. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate can-
155. Food and Drug Administration. 
158. Smith MR. Bisphosphonates to prevent skeletal complications in men with
156. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
152. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate can-
155. Food and Drug Administration. 
158. Smith MR. Bisphosphonates to prevent skeletal complications in men with
156. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
152. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate can-
155. Food and Drug Administration. 
158. Smith MR. Bisphosphonates to prevent skeletal complications in men with
156. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
152. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate can-
155. Food and Drug Administration. 
158. Smith MR. Bisphosphonates to prevent skeletal complications in men with
156. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
152. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate can-
155. Food and Drug Administration. 
158. Smith MR. Bisphosphonates to prevent skeletal complications in men with
156. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
152. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate can-
235. Potten L, Mengenstedt C, Caluag E, et al. 12-year outcomes following per-
236. monal prostate brachytherapy in patients with clinically localized prostate
238. brachytherapy for clinically localized prostate cancer: The Memorial Sloan-
240. term outcome for stages T1-T2 prostate cancer treated with permanent seed 
242. recommendations for permanent prostate brachytherapy postimplant dosi-
244. for prostate brachytherapy: effects on PSA failure and posttreatment biopsy 
245. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultra-
248. the treatment of erectile dysfunction after radiotherapy for prostate can-
250. state brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. 
251. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free 
survival for patients with a history of inflammatory bowel disease. Int J Radiat 
252. Merrick GS, Butler WM, Wallner KE, et al. Risk factors for the develop-
253. ment of prostate brachytherapy related urethral strictures. Int J Radiat 
254. Stocks CA, Stone NN, Cesaretti JA, et al. Low-dose rate prostate brachy-
255. therapy: is it worth it in patients with a history of inflammatory bowel disease? 
256. Waterman FM, Dicker AP. Probability of late rectal morbidity in 125I pros-
258. Kollmeier MA, Stock RG, Cesaretti J, et al. Urinary morbidity and inconti-
259. nence following transperineal resection of the prostate after brachytherapy. 
261. for prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. 
263. using conformal high-dose-rate brachytherapy (HDR-BT) boost with or with-
264. out neoadjuvant androgen suppression for localized prostate cancer. Int J 
265. Demannes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-
266. modulated brachytherapy: late results of a single institution experience. 
radiotherapy alone or combined with high-dose-rate brachytherapy boost for 
268. D’Amico A. Radiation and hormonal therapy for locally advanced and clini-
270. Jones CU, Hunt D, McGowan DC, et al. Radiotherapy and short-term andro-
273. brachytherapy for clinically localized prostate cancer: The Memorial Sloan-
274. Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-
275. pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant 
combined androgen suppression. Radiother Oncol Group 9413; 
277. deprivation after neoadjuvant hormonal cyproterone and radio-
278. therapy in locally advanced prostatic carcinoma: the prostate Radiation Therapy 
280. phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen 
281. deprivation before standard-dose radiotherapy for clinically localized prostate 
282. Nguyen PL, Chen MH, Beckman JA, et al. Influence of androgen depriva-
283. tion therapy on all-cause mortality in men with high-risk prostate cancer and 
a history of congestive heart failure or myocardial infarction. Int J Radiat 
285. prostate cancer: randomised controlled trial (EORTC trial 22911). Lancet 
286. D’Amico A. Radiation and hormonal therapy for locally advanced and clini-
291. state brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. 
292. Albert M, Tempany CM, Schultz D, et al. Late gastrointestinal and gastro-
293. testinal toxicity after magnetic resonance image-guided prostate brachy-
294. therapy with or without neoadjuvant external beam radiation therapy. 
295. Sasse AD, Sasse E, Carvalho AM, et al. Androgenic suppression combined 
296. with radiotherapy for the treatment of prostate adenocarcinoma: a systematic 
298. state brachytherapy: post-implantation dosimetric outcome and clinical 
300. state brachytherapy: post-implantation dosimetric outcome and clinical 
R226

Chapter 68

References


